A drug that can delay type 1: what teplizumab’s UK approval means
In August 2025 the UK approved teplizumab, its first immunotherapy that can delay the onset of type 1 diabetes. Here is what that does, and does not, mean.
In August 2025 the UK approved teplizumab, a medicine that can push back the day someone develops full type 1 diabetes. It is not a cure, and it is not for people who already have type 1. It is for a smaller group: people found, usually through screening, to be in the early stage before insulin is needed.
- Teplizumab is an immunotherapy, which means it calms the immune attack that causes type 1 rather than replacing insulin.
- In trials it delayed the start of insulin-dependent (stage 3) type 1 by around two to three years on average, which is an average across a group, not a promise for any one person.
- It is licensed for people aged 8 and over who are in stage 2: immune markers present and glucose starting to drift, but not yet needing insulin.
- Most people only learn they are stage 2 through screening, and it is offered most often to close relatives of someone who already has type 1.
- A UK licence means the medicine is judged safe and effective. Whether the NHS will fund it, and for whom, is a separate decision that comes later.
What the UK actually approved
On 14 August 2025 the UK medicines regulator, the MHRA, licensed teplizumab (brand name Tzield). It is the first immunotherapy for type 1 diabetes approved in the UK, and that word is the whole point. Every existing type 1 treatment manages the condition after it has arrived, by replacing the insulin the body has stopped making. Teplizumab is the first approved here that acts earlier, on the immune system’s attack on the insulin-making cells, to slow that attack down.
It is given as a short course of infusions over a couple of weeks, planned and supervised entirely by a specialist team. It is a one-off treatment aimed at buying time, not something anyone takes day to day, and it sits alongside insulin care rather than replacing any of it.
Stage 2, and why screening is the key
Type 1 develops in stages. In stage 1 the immune markers, called autoantibodies, are already there but glucose is still normal. In stage 2 those markers are there and glucose has started to wobble, but the person feels well and does not yet need insulin. Stage 3 is the point most people think of as diagnosis: symptoms, high glucose, and the start of insulin.
Teplizumab is for stage 2, and the catch is that most people have no idea they are in it. You usually only find out through a screening blood test, and the people most likely to be offered one are close relatives of someone who already has type 1, because their own risk is higher. If that describes your family, it is a fair thing to raise with your team.
What the delay does and does not mean
The delay seen in trials is a median across a group, roughly two years, with some later analyses suggesting longer. For one person it might be longer, for another shorter, and type 1 still comes in the end. What the delay buys is time: more months or years before the daily work of insulin begins, and more room for a person and their family to learn and prepare. It does not stop type 1, and it does nothing for someone who already lives with it.